anti-PD-L1

For patients with metastatic melanoma who fail to durably respond to PD-1 inhibitors, fecal microbiota transplantation (FMT) combined with reintroduction of anti-PD-1 therapy seems promising.

For human papillomavirus associated tumors, standard chemotherapy regimens show only limited efficacy. An ongoing phase I trial evaluating immunotherapy M7824 delivered encouraging data.